California senators advance three bills meant to crack down on health insurers
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
Category: drug pricing
A no good, very bad week for the FDA
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
AstraZeneca’s ambitious vaccine dreams are finally, officially dead
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: ‘Pharma bro’ Martin Shkreli released from prison
Martin Shkreli, the infamous ‘pharma bro’ who was sentenced to prison for securities fraud, was…
Opinion: A consultant wrote the playbook on drug pricing — then distanced himself from it
When Biogen announced the price for Aduhelm, its controversial Alzheimer’s drug, the explanation the company…
STAT+: Arkansas becomes the latest state to sue drugmakers and PBMs over insulin pricing
The Arkansas attorney general has filed a lawsuit accusing several drugmakers and pharmacy benefit managers…
STAT+: Lawmakers wade into a contentious and long-running battle over orphan drug monopolies
Sparked by an unusual, decade-long fight over a rare disease drug, two U.S. lawmakers have…
Pharma showers John Thune with campaign cash
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: J&J sues a behind-the-scenes company for exploiting its patient assistance program
In the latest dust-up over prescription drug pricing, Johnson & Johnson filed a lawsuit accusing…
The FDA’s Rob Califf on importing drugs from Canada, on Aduhelm, and on opioids
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: Would drugmakers lower their insulin prices if Congress asks nicely?
WASHINGTON — After a yearslong, drawn-out debate over how to best lower patients’ prescription drug…
STAT+: California fines an OptumRx pharmacy for jeopardizing patient health. Is that enough?
The California Board of Pharmacy fined OptumRx, one of the largest pharmacy benefit managers in…
STAT+: Usual and customary? Rite Aid ordered to pay Humana $123 million for inflating pharmacy claims
Rite Aid was ordered by an arbitrator to pay nearly $123 million to Humana, one…
STAT+: Manchin won’t support new health policy unless Congress rolls back Trump tax cuts
WASHINGTON — Sen. Joe Manchin, a moderate Democrat who will determine how much domestic policy…
The FDA’s ban on menthol in cigarettes clears a major regulatory hurdle
D.C. Diagnosis is STAT’s weekly newsletter about the politics and policy of health and medicine….
STAT+: Biden is urged to pursue march-in rights for a pricey cancer drug after NIH delays a petition review
Citing arguments by more than two dozen legal experts, Sen. Elizabeth Warren (D-Mass.) is urging…
STAT+: U.S. spending on pharmaceuticals jumped 12% in 2021, fueled by costs of Covid-19 vaccines and therapies
Thanks to Covid-19 vaccines and therapies, U.S. spending on pharmaceuticals rose 12% in 2021 as…
STAT+: Pfizer faces criticism for arguing that intellectual property for its Covid-19 pill is a human right
Numerous advocacy groups and institutional shareholders are chiding Pfizer for arguing that its intellectual property…
Biogen’s head-scratching new lobbyist hire
D.C. Diagnosis is STAT’s weekly newsletter about the politics and policy of health and medicine….
STAT+: Nation’s top cancer hospitals slap hefty markups on drugs, study says
The nation’s preeminent cancer hospitals are charging commercial health insurers anywhere from double to seven…
The next battle in the never-ending war over Aduhelm
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: A $2.1 million price tag for Bluebird Bio’s gene therapy is cost-effective, analysis finds
As the U.S. health care system braces for expensive gene therapies, a new analysis suggests…
STAT+: Will Biogen sue Medicare over its restrictions on the Alzheimer’s drug, Aduhelm? And other big legal questions about the decision
WASHINGTON — Biogen and other drugmakers have already hinted they might sue Medicare over its…
Human Rights Watch says unaffordable U.S. insulin is a human rights abuse
WASHINGTON — Insulin prices are sky high. High enough, now, that Human Rights Watch is…
STAT+: ‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval
Whither accelerated approval? Amid the hubbub over new Medicare coverage restrictions for Alzheimer’s treatments, a…
STAT+: Many Medicare Part D beneficiaries don’t fill prescriptions for high-priced medicines
Medicare Part D beneficiaries who have low incomes and receive government subsidies were nearly twice…
STAT+: Colombian government faces calls to issue compulsory license for Pfizer’s Covid-19 pill
In the latest bid to expand access to the Pfizer Covid-19 pill, several advocacy groups…
Faced with high drug prices, seniors are abandoning cancer drugs at the pharmacy
The pressure on Medicare just keeps ramping up Medicare is set to decide this month…
Opinion: In the future, we should spend more on prescription drugs, not less
The conventional wisdom that we need to reduce spending on prescription drugs is all wrong….
.jpg)
STAT+: Medicare Part D and its beneficiaries could have saved millions if more biosimilars were accessible
Amid ongoing debate over biosimilar use in the United States, a new government analysis found…
STAT+: Mark Cuban’s company is building a ‘parallel supply chain’ for prescription drugs
Mark Cuban’s drug company started with an ambitious premise: to circumvent middlemen to offer cheaper…
STAT+: Pharmalittle: Advisory panel narrowly votes down ALS drug; Vertex looks to advance experimental pain drug
Good morning. Elizabeth Cooney here, borrowing the virtual Pharmalittle chair while Ed Silverman takes Manhattan…
STAT+: HHS seeks to penalize another drugmaker amid legal clash over drug discount program
The U.S. Health and Resources Administration is seeking to penalize Boehringer Ingelheim for curtailing discounts…
STAT+: Inflation caused ‘unprecedented’ drops in net pharmaceutical prices, analysis finds
Amid ongoing turmoil over the cost of prescription medicines, a new analysis finds that brand-name…
STAT+: Despite competition, U.S. cancer drug prices rose even as they fell in Germany and Switzerland
Even as prices rose substantially in the U.S. over a recent 12-year period, a new…
Before Aduhelm, Billy Dunn was a superstar at the FDA
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: The biggest PBMs are handling more and more of the country’s drug price negotiations
Alex Schmelzer didn’t think he’d be the most-hated person in drug pricing negotiations, but he…
Listen: Doing biotech in Ukraine, drug pricing déjà vu, & Covid surges overseas
How should pharma treat Russia? Why can’t Congress pass a drug pricing bill? And what…
STAT+: Lawmakers accuse PhRMA of providing ‘misleading information’ about drug price hikes
A group of Congressional lawmakers is accusing the pharmaceutical industry’s leading trade group of providing…
Inside the push for a permanent pandemic preparedness office at the White House
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: Three years after the Senate grilled drug makers … nothing’s changed
WASHINGTON – Back in 2019, when the Senate Finance Committee called seven drug industry executives…
STAT+: Cutting-edge gene therapies could be coming for sickle cell. Will Medicaid patients be able to access them?
Gary Puckrein sees a dilemma coming that has him excited, and at the same time,…
STAT+: In New York appearance, CMS administrator pushes for Congress to act on drug prices
NEW YORK — When Chiquita Brooks-LaSure, the Biden official who oversees the Medicare and Medicaid health…
STAT+: Mallinckrodt to pay $260 million to settle federal lawsuits over Medicaid rebates and kickbacks
After years of squabbling, Mallinckrodt agreed to pay $260 million to settle accusations that it…
Covid budget crunch looms over government funding fight
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: Civica Rx has an ambitious plan to make low-cost insulin for all Americans. But can it work?
In an unconventional bid to widen access to insulin for Americans, a nonprofit announced plans…
STAT+: Nevada joins a little-known, ambitious state consortium dedicated to better drug prices
After months of talks, the state of Nevada has joined a consortium formed by Oregon…
In State of the Union, Biden walks a fine line on Covid optimism
WASHINGTON — President Biden on Tuesday vowed that the U.S. won’t become complacent in its…
STAT+: Oregon withdraws a waiver request to run a closed Medicaid formulary
In response to a raft of concerns, Oregon has withdrawn a request made to federal…
STAT+: NIH official accused of ‘bias’ against using a controversial law to address high drug prices
The campaign to use so-called march-in rights to widen access to a cancer drug is…